Table 2. Clinical characteristics of... | American Society of Hematology

Table 2.

Clinical characteristics of CC-90009 responders and partial/nonresponders

	Responders (n = 24)	Partial/nonresponders (n = 11)
De novo vs secondary/relapsed AML (n)	n = 21	n = 10
De novo	14	8
Secondary/relapsed	7	2
MRC cytogenetic risk at diagnosis (n)	n = 23	n = 11
Intermediated	15	9
Adverse	8	2
Normal vs abnormal cytogenetic AML (n)	n = 24	n = 11
Normal	13	7
Abnormal	11	4
LSC17 score (n)	n = 24	n = 11
High score	17	10
Low score	7	1

	Responders (n = 24)	Partial/nonresponders (n = 11)
De novo vs secondary/relapsed AML (n)	n = 21	n = 10
De novo	14	8
Secondary/relapsed	7	2
MRC cytogenetic risk at diagnosis (n)	n = 23	n = 11
Intermediated	15	9
Adverse	8	2
Normal vs abnormal cytogenetic AML (n)	n = 24	n = 11
Normal	13	7
Abnormal	11	4
LSC17 score (n)	n = 24	n = 11
High score	17	10
Low score	7	1

Secondary includes therapy-related AML and after myelodysplastic/myeloproliferative neoplasm AML.

MRC, Medical Research Council classification.